Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2019-09-20 | Charles J. Fisher, Jr., M.D., Chairman and Director Dr. Fisher became a Director in November 2017 and was appointed Chairman on November 27, 2017. ... Our Board of Directors presently has an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee, on each of which Drs. Fisher and Shah, Mr. Broenniman and Ms. Johnson serve as independent directors. Director Compensation for 2019 Fiscal Year Dr. Fisher earned $124,000 in cash compensation for his services as non-executive Chairman and $34,000 in Board fees related to his role as a director and a member of our Audit Committee for an aggregate cash amount of $124,000. Dr. Fisher also received RSUs valued at $35,000 for his ongoing service as a Board member per the 2012 Directors Compensation Program. |
| 2020-07-28 | Charles J. Fisher, Jr., M.D., Chairman and Director, Age 74. Dr. Fisher has served as a director of the Company and as our Chairman since November 2017. Dr. Fisher also serves on the Audit Committee, Compensation Committee and Nominating and Governance Committee. Director compensation for 2020 fiscal year: $159,000. |
| 2021-07-28 | In the fiscal year ended March 31, 2021, Dr. Fisher earned $52,500 in Board fees for his role as a director. Dr. Fisher also received RSU’s valued at $35,000 for his ongoing service as a Board member pursuant to the Non-Employee Directors Compensation Program. |
| 2022-07-27 | Dr. Fisher has served as a director of the Company since November 2017. Dr. Fisher served as our Chairman from November 2017 until he was appointed our Chief Executive Officer in October 2020. Previously, Dr. Fisher was Executive Chairman and Chief Executive Officer of Seastar Medical, Inc., a biotechnology company, from 2013 to July 2019. Dr. Fisher also has served as Chief Executive Officer of Margaux Biologics, Inc., a biotechnology company, since 2010. Prior to founding Margaux Biologics, he was Chief Medical Officer and Executive Vice President of Cardiome Pharma Corp. from 2005 to 2010, where he led the team that invented, developed, registered vernakalant, a novel, first in class, multi-ion channel drug for atrial fibrillation, Brinavess. Dr. Fisher served as Head, Section of Critical Care Medicine at The Cleveland Clinic Foundation, and has held Professor, Division Chief and director positions at the University of California at Davis Medical Center, Case Western Reserve University and The Cleveland Clinic Foundation. His research in sepsis, inflammation, host defense and endothelial dysfunction led to his recruitment to Eli Lilly & Co., where he led the Xigris (activated Protein C) Global Product Team and successfully registered the first drug approved for the treatment of sepsis. Previously, he was Vice President for Global Pharmaceutical Development at Abbott Laboratories where, among other accomplishments, he guided the registration of Humira. Additionally, Dr. Fisher is a multi-tour combat veteran, with extensive military experience in Special Operations. He has served as a member of the Defense Science Research Council and on DARPA panels, including one focused on universal host defense. Dr. Fisher received his Bachelor’s degree and Medical Degree from Michigan State University. We believe Dr. Fisher is qualified to serve as our director because of his strong background and experience in the life sciences industry and with public companies. |
| Filing Date | Source Excerpt |
|---|---|
| 2010-06-09 | Charles J. Fisher, Jr., M.D. Director 63 The Compensation Committee is responsible for recommending and reviewing the compensation, including options and perquisites, of the Companys officers and other employees. The Compensation Committee, currently consisting of Messrs. Bowes and Van Ness and Dr. Fisher, held 3 meetings during 2009. |
Data sourced from SEC filings. Last updated: 2026-02-03